IV Contrast-Enhanced Cone Beam Computed Tomography (CBCT) in Radiotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

EARLY_PHASE1

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-01

Study Completion Date

2021-05-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find out if giving intravenous (IV) contrast (a liquid that helps with the visibility of organs and blood vessels that is given through the vein with the use of a hollow needle) during a Cone Beam Computed Tomography (CBCT- a type of computerized X-ray) can help people who have image guided radiation therapy (IGRT) for the treatment of abdominal and pelvic tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

In-Room PET in Proton Radiation Therapy

NCT01228448

Brain Tumor Head and Neck Tumor Skull Base Tumor

COMPLETED NA

Improving Clinical PET/CT Image Quality in Retrospectively Reconstructed Breath-Hold Images

NCT01109953

Lung Cancer

TERMINATED

Validating Low FDG Dose PET/CT Compared to Current Standard of Care Dose PET/CT

NCT03519659

PET/CT Imaging

ACTIVE_NOT_RECRUITING NA

Patient- and Task-specific Radiation Dose Optimization for Pediatric Abdominopelvic CT Applications

NCT03429712

Split Dose CT

TERMINATED NA

PET-CT Imaging With PCD-CT

NCT07242690

Head and Neck Cancer (H&N)

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The goal of this pilot study is to determine the feasibility and utility of administering IV contrast during a Cone Beam Computed Tomography (CBCT) in subjects who have image guided radiation therapy (IGRT) for the treatment of abdominal and pelvic tumors. Participant duration is one visit.

Subjects will be required to fast for at least 2 hours prior to study procedures, as determined by the treating physician based on the site to be irradiated. An 18- to 22-gauge peripheral IV will be placed in the subject's arm prior to being brought to clinical treatment room. The patient will be placed in position for radiotherapy as per standard of care and will be connected to IV contrast injector. Standard of care IGRT techniques will be performed to confirm correct positioning. Iodinated IV contrast will be administered and the contrast enhance cone beam CT will be initiated. Treatment will then be administered with the patient in the position determined by non-contrast cone beam CT, as per standard of care. Immediately after completion of treatment of the subject, the study physician will complete physician survey of attitude about the utility of contrast-enhanced cone beam CT.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pelvic Cancer Abdominal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Subjects will receive contrast enhanced CBCT prior to RT treatment.

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Contrast Enhanced Cone Beam CT

60 seconds after the start of the administration of IV contrast, cone beam CT will be initiated.

Group Type EXPERIMENTAL

Omnipaque 300mg/mL Solution for Injection

Intervention Type DRUG

Prior to the contrast enhanced Cone Beam CT, 100mL of Omnipaque will be administered by IV at a rate of 2mL per second, followed by administration of 50mL of 0.9% saline.

Cone Beam CT

Intervention Type RADIATION

60 seconds after contrast administration, a Cone Beam CT will be performed.

Radiation Therapy

Intervention Type RADIATION

Standard of Care Radiation Therapy will be administered, dosage depends on the type of tumor being treated.

0.9% Saline

Intervention Type DRUG

50 ML of 0.9% Saline will be administered immediately after Omnipaque administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Omnipaque 300mg/mL Solution for Injection

Prior to the contrast enhanced Cone Beam CT, 100mL of Omnipaque will be administered by IV at a rate of 2mL per second, followed by administration of 50mL of 0.9% saline.

Intervention Type DRUG

Cone Beam CT

60 seconds after contrast administration, a Cone Beam CT will be performed.

Intervention Type RADIATION

Radiation Therapy

Standard of Care Radiation Therapy will be administered, dosage depends on the type of tumor being treated.

Intervention Type RADIATION

0.9% Saline

50 ML of 0.9% Saline will be administered immediately after Omnipaque administration

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Iohexol Saline Solution

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject must be greater than or equal to 18 years of age.
2. Subject must be able and willing to sign a written informed consent document.
3. Subject requiring image-guided external beam radiotherapy to abdominal or pelvic tumor with cone beam CT deemed clinically necessary by the treating physician.
4. No history of prior allergic reaction to intravenous CT contrast medium.
5. Creatinine of less than 1.9 mg/dL measured within one month prior to enrollment on the study.
6. No administration of intravenous contrast within 24 hours of administration of intravenous contrast on protocol.
7. Ability to complete New York Presbyterian Hospital iodinated contrast media administration questionnaire.
8. Negative pregnancy test for females of childbearing potential, in accordance to institutional guidelines.
9. Ability to fast for at least 2 hours prior to study procedures.
10. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-3.

Exclusion Criteria

1. Known allergy to iohexol or any iodinated intravenous contrast medium.
2. Fluid overload that would contraindicate bolus administration of intravenous contrast.
3. Pregnant or nursing subjects.
4. Presence of single kidney or transplanted kidney
5. Acute renal failure
6. Chronic renal insufficiency, stage IV or V.
7. Administration of iodinated intravenous CT contrast medium within 24 hours of study procedures.
8. Inability to fast for at least 2 hours prior to study procedures.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No